Cancer
Conditions
Keywords
Randomized controlled trial, Neoplasm, Communication, Complementary medicine, Integrative care, Integrative medicine
Brief summary
The purpose of this phase two parallel-group randomized controlled trial is to assess the efficacy of open dialogue about CAM integrated in conventional oncology care. The investigators hypothesize that patients in the intervention group participating in a scheduled open dialogue with a nurse specialist about CAM will experience better physical and mental health compared to patients in the control group receiving standard care alone.
Detailed description
Patients randomized to the intervention group will participate in a scheduled open dialogue about CAM with a specialist nurse, who has completed the Fellowship in Integrative Medicine at the University of Arizona. This is a training program for health professionals in empowering individuals and communities to optimize health and well-being through evidence-based, sustainable and integrative approaches. The open dialogue will be based on the fundamentals of person-centered care according to this program and include patient preferences and wishes, reliable information and counselling and advice about the potential risks and benefits of using CAM as an adjunct to conventional oncology care. All dialogue, each lasting approximately 60 minutes, will be conducted by the same nurse as soon as possible and at the latest two weeks after enrolment. According to patient needs and wishes there may be a follow-up dialogue over the telephone or in the Oncology Outpatient Clinic. The potential second dialogue is estimated to last approximately 30 minutes. Participants in the control group will receive standard information including reference to www.KABcancer.dk, which is a website presenting research on CAM, including information about its potential effects and outcomes.
Interventions
OTHEROpen dialogue about complementary alternative medicine
1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
OTHERStandard care
Standard care including referral to a homepage about CAM
Sponsors
Vejle Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 or more * Speaks and reads Danish * Diagnosed with a new primary cancer or a relapse of cancer within the last 3 months * Planned or initiated medical oncology treatment at the Department of Oncology, Vejle Hospital * At least two months of oncology treatment is realistic based on clinical assessment * Life expectancy of at least six months * Informed consent
Exclusion criteria
-Participation in other trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in frequency of adverse events grade 3-4 between the two arms | 8 weeks after enrolment | Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAEv5) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in patient reported quality of life between the two arms | At baseline and after 12 and 24 weeks | Quality of life will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30). The EORTC is composed of both multi item scales and single item measures. These include five functional scales, three symptom scales, a global health status and six single items. All of the scales and single items measures range in score from 0 to 100. A high score for functional scale represents a high/health level of functioning. A high score for the global health status represents a high quality of life. A high score for a symptom scale represents a high level of symptomatology/problems |
| Difference in patients' evaluation of received information between the two arms | At baseline and after 12 and 24 weeks | Evaluation of received information will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Information Questionnaire (EORTC QLQ-INFO25). |
| Difference in patient reported degree of anxiety and depression between the two arms | At baseline and after 12 and 24 weeks | Anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS) |
| Difference in frequency of adverse events grade 3-4 between the two arms | At baseline and after 12 and 24 weeks | Frequency of adverse events grade 3-4 will be measured by using Common Terminology Criteria for Adverse Events (CTCAEv5) |
Countries
Denmark
Outcome results
None listed